Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
Covered in this story
Call it yourself
No calls on $MYGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Myriad Genetics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.